Clinical comparison of Provisc and Healon (1% sodium hyaluronate) in cataract surgery

Clinical comparison of Provisc and Healon in cataract surgery.

Article specifications

This prospective, randomized, multicenter clinical trial was published in 1995 in journal of cataract and refractive surgery (IF 2015:3.02) by American ophthalmologists.

In this study the efficacy and safety of Healon® (1% sodium hyaluronate) and Provisc® (1% sodium hyaluronate) in 61 patients needed extracapsular cataract extraction (ECCE) and posterior chamber IOL implantation, divided in 2 groups :29 patients had cataract surgery with Healon® and 32 patient with Provisc®. Patients were examined preoperatively and 1 day and 3 to 16 days postoperatively. These examinations included visual acuity, lOP, and ocular signs and symptoms.

Results

The results of this randomized, prospective study indicate that Provisc (1% sodium hyaluronate) and Healon (1% sodium hyaluronate) are equally useful and safe cataract surgical aids. There were no statistically significant differences between treatment groups with regard to preoperative versus postoperative corneal thickness, incidence and magnitude of corneal edema and of iritis, and magnitude of lOP changes over baseline. Intraoperative and postoperative complications were few, not serious, and not related to viscoelastic use. No adverse reactions occurred during the course of the study. The results indicate that Provisc and Healon are clinically equivalent, safe, and effective cataract surgical aids.